AstraZeneca India posts FY 2023-24 revenue higher at Rs. 1,330 Cr
Profit Before Tax is Rs. 220 crore, registering a commendable 64% growth
Profit Before Tax is Rs. 220 crore, registering a commendable 64% growth
Launch of 20 new medicines expected by 2030
According to IQVIATM sales data for the 12-month period ending March 2024, the Combigan Ophthalmic Solution, 0.2%|0.5% market achieved annual sales of approximately $290.0 million
35,000 doctors from across India pledged their support for the initiative to raise awareness about cardiovascular diseases
Annapurna will lead the company in India ensuring patient access to its highly innovative medicines and vaccines
EBITDA before special items falls 1.3 percent to € 4.41 billion
Sanofi India has reported total income of Rs. 738.9 crores during the period ended March 31, 2024
The JV successfully leveraged the strengths of both companies to better serve the fast-growing Indian market
Acquisition encompasses a portfolio of RLT programs across a range of solid tumor indications
Subscribe To Our Newsletter & Stay Updated